Volume 72, Issue 2

Search all Cancer Immunology, Immunotherapy articles

February 2023

20 articles in this issue

CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
Thamizhselvi Ganapathy
Rajalingam Radhakrishnan
Sunil Martin
Review Article 12 August 2022 Pages: 277 - 286
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens
Helen Cho
Joe Binder
Robert E. Hollingsworth
Original Article 13 July 2022 Pages: 287 - 300
Personalized tumor vaccine for pancreatic cancer
Shira Orr
Ling Huang
David Avigan
Original Article 14 July 2022 Pages: 301 - 313
High abundance of Lachnospiraceae in the human gut microbiome is related to high immunoscores in advanced colorectal cancer
Zhang Hexun
Toru Miyake
Masaji Tani
Original Article 22 July 2022 Pages: 315 - 326
Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma
Haimeng Yan
Donghua He
Zhen Cai
Original Article 26 July 2022 Pages: 327 - 338
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
Yinjie Gao
Michelle M. Stein
Sandip P. Patel
Original Article Open access 26 July 2022 Pages: 339 - 350
A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment
Cheng-Liang Kuo
Han-Yu Chou
Alan Yueh-Luen Lee
Original Article Open access 27 July 2022 Pages: 351 - 369
Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma
Seung Hyuck Jeon
Yong Joon Lee
Eui-Cheol Shin
Original Article 28 July 2022 Pages: 371 - 384
Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy
Mengchao An
Wenkang Wang
Zibing Wang
Original Article 30 July 2022 Pages: 385 - 395
Single-cell analysis of peripheral CD8⁺ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer
Niloufar Khojandi
Louis Connelly
Ryan M. Teague
Original Article 30 July 2022 Pages: 397 - 408
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer
Jiannan Chen
Jianhua Hu
Zhigang Guo
Original Article 04 August 2022 Pages: 409 - 425
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab
Tatsuki Ikoma
Mototsugu Shimokawa
Hironaga Satake
Original Article 04 August 2022 Pages: 427 - 435
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients
Shumin Yuan
Ling Peng
Zibing Wang
Original Article 05 August 2022 Pages: 437 - 448
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients
Yu Feng
Le Tang
Yuankai Shi
Original Article 07 August 2022 Pages: 449 - 459
Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma
Kasper Munch Lauridsen
Marianne Hokland
Morten Nørgaard Andersen
Original Article 11 August 2022 Pages: 461 - 473
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
Emiel A. De Jaeghere
Sandra Tuyaerts
Hannelore G. Denys
Original Article Open access 12 August 2022 Pages: 475 - 491
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies
Jie Wang
Chen Li
Feng Guo
Original Article 13 August 2022 Pages: 493 - 507
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma
Xin-Wen Zhang
Alexander Wald
Jessica C. Hassel
Research Report Open access 16 July 2022 Pages: 509 - 513
Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma
Alexej Ballhausen
Amin Ben Hamza
Leo Hansmann
Research Report Open access 10 August 2022 Pages: 515 - 521
Bloody pericardial effusion during chemotherapy with immune checkpoint inhibitors
Yuika Sasatani
Eiji Ojima
Hiroaki Satoh
Letter to the Editors 25 July 2022 Pages: 523 - 525

Volume 72, Issue 2

CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?

Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens

Personalized tumor vaccine for pancreatic cancer

High abundance of Lachnospiraceae in the human gut microbiome is related to high immunoscores in advanced colorectal cancer

Interleukin-32γ promotes macrophage-mediated chemoresistance by inducing CSF1-dependent M2 macrophage polarization in multiple myeloma

Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment

Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma

Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy

Single-cell analysis of peripheral CD8⁺ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer

Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer

Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab

Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study

Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies

Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma

Bloody pericardial effusion during chemotherapy with immune checkpoint inhibitors

Navigation